PDE5 inhibitors blunt inflammation in human BPH: A potential mechanism of action for PDE5 inhibitors in LUTS

Prostate

Volumn 73, Issue 13, 2013, Pages 1391-1402

  Vignozzi, Linda ^a   Gacci, Mauro ^b   Cellai, Ilaria ^a   Morelli, Annamaria ^a   Maneschi, Elena ^a   Comeglio, Paolo ^a   Santi, Raffaella ^b   Filippi, Sandra ^a   Sebastianelli, Arcangelo ^b   Nesi, Gabriella ^b   Serni, Sergio ^b   Carini, Marco ^b   Maggi, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

BPH LUTS; inflammation; lipids; metabolic syndrome; PDE5 inhibitors; prostate; tadalafil; vardenafil

Indexed keywords

ANTIHYPERTENSIVE AGENT; CD45 ANTIGEN; CYCLIC GMP DEPENDENT PROTEIN KINASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 8; KT 5823; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SP 8 BROMO PET CYCLIC GMP; TADALAFIL; TAMSULOSIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VARDENAFIL;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLUNT INFLAMMATION; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; INFLAMMATORY INFILTRATE; LOWER URINARY TRACT SYMPTOM; MALE; METABOLIC SYNDROME X; MYOFIBROBLAST; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

BPH/LUTS; INFLAMMATION; LIPIDS; METABOLIC SYNDROME; PDE5 INHIBITORS; PROSTATE; TADALAFIL; VARDENAFIL;

AGED; AGED, 80 AND OVER; CARBOLINES; CYCLIC GMP; DOUBLE-BLIND METHOD; HUMANS; IMIDAZOLES; INFLAMMATION; INTERLEUKIN-8; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; MYOFIBROBLASTS; PHOSPHODIESTERASE 5 INHIBITORS; PILOT PROJECTS; PIPERAZINES; PROSTATE; PROSTATIC HYPERPLASIA; SULFONES; TREATMENT OUTCOME; TRIAZINES;

EID: 84882278739     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22686     Document Type: Article

References (52)

1. Despre JP, Lemieux I,. Abdominal obesity and metabolic syndrome. Nature 2006; 14: 881-887.
2. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK,. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012; 61: 560-570.
3. Hammarste J, Hogstedt B,. Calculated fast-growing benign prostatic hyperplasia-A risk factor for developing clinical prostate cancer. Scand J Urol Nephrol 2002; 36: 330-338.
4. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D,. Components of the metabolic syndrome-Risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998; 1: 157-162.
5. Ochiai A, Fritsche HA, Babaian RJ,. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. Urology 2005; 66: 819-823.
6. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, Landis P, Platz EA,. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91: 2562-2568.
7. Nandeesha H, Koner BC, Dorairajan LN, Sen SK,. Hyperinsulinemia and dyslipidaemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 2006; 370: 89-93.
8. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW,. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002; 168: 599-604.
9. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A,. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007; 51: 199-203.
10. Vikram A, Gopabandhu J, Ramarao P,. Insulin-resistance and benign prostatic hyperplasia: The connection. Eur J Pharmacol 2010; 641: 75-81.
11. Vikram A, Jena GB, Ramarao P,. Increased cell proliferation and contractility of prostate in insulin resistant rats: Linking hyperinsulinemia with benign prostate hyperplasia. Prostate 2010; 70: 79-89.
12. Vignozzi L, Gacci M, Cellai I, Santi R, Corona G, Morelli A, Rastrelli G, Comeglio P, Sebastanelli A, Maneschi E, Nesi G, De Nunzio C, Tubaro A, Mannucci E, Carini M, Maggi M,. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 2013; 73 (8): 789-800.
13. Kim J, Di Vizio D, Kim TK, Kim J, Kim M, Pelton K, Clinton SK, Hai T, Hwang D, Solomon KR, Freeman MR,. The response of the prostate to circulating cholesterol: Activating transcription factor 3 (ATF3) as a prominent node in a cholesterol-sensing network. PLoS ONE 2012; 7: e39448. doi: 10.1371/journal. pone.0039448
14. Vignozzi L, Cellai I, Santi R, Lombardelli L, Morelli A, Comeglio P, Filippi S, Logiodice F, Carini M, Nesi G, Gacci M, Piccinni MP, Adorini L, Maggi M,. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol 2012; 214: 31-43.
15. Zhou D, Li S, Wang X, Cheng B, Ding X,. Estrogen receptor alpha is essential for the proliferation of prostatic smooth muscle cells stimulated by 17β-estradiol and insulin-like growth factor 1. Cell Biochem Funct 2011; 29: 120-125.
16. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M,. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010; 33: 475-488.
17. Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M,. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012; 61: 994-1003.
18. Liu L, Zheng S, Han P, Wei Q,. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review and meta-analysis. Urology 2011; 77: 123-129.
19. Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L,. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011; 30: 292-301.
20. Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG,. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011; 60: 809-825.
21. Giuliano F, Uckert S, Maggi M, Birder L, Kissel J, Viktrup L,. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 2013; 63: 506-516.
22. Morelli A, Filippi S, Sandner P, Fibbi B, Chavalmane AK, Silvestrini E, Sarchielli E, Vignozzi L, Gacci M, Carini M, Vannelli GB, Maggi M,. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med 2009; 6: 1594-1608.
23. Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, Gacci M, Vignozzi L, Carini M, Vannelli GB, Maggi M,. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 2011; 8: 2746-2760.
24. Morelli A, Filippi S, Comeglio P, Sarchielli E, Chavalmane AK, Vignozzi L, Fibbi B, Silvestrini E, Sandner P, Gacci M, Carini M, Vannelli GB, Maggi M,. Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. J Sex Med 2010; 7: 107-120.
25. Behr-Roussel D, Oger S, Caisey S, Sandner P, Bernabé J, Alexandre L, Giuliano F,. Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord injured rats. Eur Urol 2011; 59: 272-277.
26. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, Gacci M, Vignozzi L, Vannelli GB, Carini M, Forti G, Maggi M,. Characterization and functional role of androgen dependent PDE5 activity in the bladder. Endocrinology 2007; 148: 1019-1029.
27. Filippi S, Vignozzi L, Morelli A, Chavalmane AK, Sarchielli E, Fibbi B, Saad F, Sandner P, Ruggiano P, Vannelli GB, Mannucci E, Maggi M,. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med 2009; 6: 3274-3288.
28. Mallidis C, Czerwiec A, Filippi S, O'Neill J, Maggi M, McClure N,. Spermatogenic and sperm quality differences in an experimental model of metabolic syndrome and hypogonadalhypogonadism. Reproduction 2011; 142: 63-71.
29. Vignozzi L, Morelli A, Filippi S, Comeglio P, Chavalmane AK, Marchetta M, Toce M, Yehiely-Cohen R, Vannelli GB, Adorini L, Maggi M,. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J Sex Med 2011; 8: 57-77.
30. Morelli A, Vignozzi L, Maggi M, Adorini L,. Farnesoid X receptor activation improves erectile dysfunction in models of metabolic syndrome and diabetes. Biochim Biophys Acta 2011; 1812: 859-866.
31. Vignozzi L, Morelli A, Sarchielli E, Comeglio P, Filippi S, Cellai I, Maneschi E, Serni S, Gacci M, Carini M, Piccinni MP, Saad F, Adorini L, Vannelli GB, Maggi M,. Testosterone protects from metabolic syndrome-associated prostate inflammation: An experimental study in rabbit. J Endocrinol 2012; 212: 71-84.
32. Morelli A, Comeglio P, Filippi S, Sarchielli E, Cellai I, Vignozzi L, Yehiely-Cohen R, Maneschi E, Gacci M, Carini M, Adorini L, Vannelli GB, Maggi M,. Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. J Steroid Biochem Mol Biol 2012; 132: 80-92.
33. Morelli A, Comeglio P, Filippi S, Sarchielli E, Vignozzi L, Maneschi E, Cellai I, Gacci M, Lenzi A, Vannelli GB, Maggi M,. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: An experimental study in the rabbit. Prostate 2013; 73: 428-441.
34. Penna G, Fibbi B, Amuchastegui S, Cossetti C, Aquilano F, Laverny G, Gacci M, Crescioli C, Maggi M, Adorini L,. Human Benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol 2009; 182: 4056-4064.
35. Vignozzi L, Filippi S, Morelli A, Comeglio P, Cellai I, Sarchielli E, Maneschi E, Mancina R, Gacci M, Vannelli GB, Maggi M,. Testosterone/estradiol ratio regulates NO-induced bladder relaxation and responsiveness to PDE5 inhibitors. J Sex Med 2012; 9: 3028-3040.
36. Vignozzi L, Vannelli GB, Morelli A, Mancina R, Marini M, Ferruzzi P, Crescioli C, Luconi M, Donati S, Fisher AD, Baldi E, Filippi S, Forti G, Maggi M,. Identification, characterization and biological activity of oxytocin receptor in the developing human penis. Mol Hum Reprod 2005; 11: 99-106.
37. Zhang XH, Filippi S, Vignozzi L, Morelli A, Mancina R, Luconi M, Donati S, Marini M, Vannelli GB, Forti G, Maggi M,. Identification, localization and functional in vitro and in vivo activity of oxytocin receptor in the rat penis. J Endocrinol 2005; 184: 567-576.
38. Zhang XH, Morelli A, Luconi M, Vignozzi L, Filippi S, Marini M, Vannelli GB, Mancina R, Forti G, Maggi M,. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol 2005; 47: 409-416.
39. Gacci M, Vittori G, Tosi N, Siena GP, Rossetti MA, Lapini A, Vignozzi L, Serni S, Maggi M, Carini M,. A randomised, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg versus tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med 2012; 9: 1624-1633.
40. Corona G, Mannucci E, Petrone L, Schulman C, Balercia G, Fisher AD, Chiarini V, Forti G, Maggi M,. A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunction. J Sex Med 2007; 4: 789-796.
41. Gacci M, Vignozzi L, Sebastianelli A, Salvi M, Giannessi C, De Nunzio C, Tubaro A, Corona G, Rastrelli G, Santi R, Nesi G, Serni S, Carini M, Maggi M,. Metabolic syndrome and lower urinary tract symptoms: The role of inflammation. Prostate Cancer Prostatic Dis 2013; 16: 101-106.
42. Schaffner CP, Gordon HW,. The hypocholesterolemic activity of orally administered polyene macrolides. Proc Natl Acad Sci USA 1968; 61: 36-41.
43. Wang GM, Schaffner CP,. Effect of candicidin and colestipol on the testes and prostate glands of BIO 87.20 hamsters. Invest Urol 1976; 14: 66-71.
44. Pelton K, Di Vizio D, Insabato L, Schaffner CP, Freeman MR, Solomon KR,. Ezetimibe reduces enlarged prostate in an animal model of benign prostatic hyperplasia. J Urol 2010; 184: 1555-1559.
45. Ahluwalia A, Foster P, Scotland RS, McLean PG, Mathur A, Perretti M, Moncada S, Hobbs AJ,. Antiinflammatory activity of soluble guanylate cyclase: cGMP-Dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci USA 2004; 101: 1386-1391.
46. Kiemer AK, Hartung T, Vollmar AM,. cGMP-mediated inhibition of TNF-alpha production by the atrial natriuretic peptide in murine macrophages. J Immunol 2000; 165: 175-181.
47. Mitkiewicz M, Kuropatwa M, Kurowska E, Gorczyca WA,. Different effects of soluble and particulate guanylylcyclases on expression of inflammatory cytokines in rat peripheral blood mononuclear cells. Immunobiology 2011; 216: 423-430.
48. Roumeguère T, Zouaoui Boudjeltia K, Babar S, Nuyens V, Rousseau A, Van Antwerpen P, Ducobu J, Wespes E, Vanhaeverbeek M,. Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha. Eur Urol 2010; 57: 522-528.
49. Li Y, Tong X, Maimaitiyiming H, Clemons K, Cao JM, Wang S,. Overexpression of cGMP-dependent protein kinase I (PKG-I) attenuates ischemia-reperfusion-induced kidney injury. Am J Physiol Renal Physiol 2012; 302: F561-F570.
50. Rentsendorj O, Damarla M, Aggarwal NR, Choi JY, Johnston L, D'Alessio FR, Crow MT, Pearse DB,. Knockdown of lung phosphodiesterase 2A attenuates alveolar inflammation and protein leak in a two-hit mouse model of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2011; 301: L161-L170.
51. Lutz SZ, Hennige AM, Feil S, Peter A, Gerling A, Machann J, Kröber SM, Rath M, Schürmann A, Weigert C, Häring HU, Feil R,. Genetic ablation of cGMP-dependent protein kinase type I causes liver inflammation and fasting hyperglycemia. Diabetes 2011; 60: 1566-1576.
52. Werner CG, Godfrey V, Arnold RR, Featherstone GL, Bender D, Schlossmann J, Schiemann M, Hofmann F, Pryzwansky KB,. Neutrophil dysfunction in guanosine 3′,5′-cyclic monophosphate-dependent protein kinase I-deficient mice. J Immunol 2005; 175: 1919-1929.